Aquestive Therapeutics, Inc.
corporate_fare Company Profile
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AQST at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Aquestive Therapeutics Secures $5M Equity Commitment, Extends Anaphylm Regulatory Deadline, and Reports Q4/FY25 Results
- Aquestive Therapeutics Outlines Anaphylm Resubmission Timeline and 2026 Cash Runway in Investor Presentation
- Aquestive Therapeutics Receives FDA Complete Response Letter for Anaphylm, Citing Packaging & Administration Deficiencies
- FDA Identifies Deficiencies in Anaphylm NDA, Potentially Delaying Approval
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$44.55M
Net Income
-$83.78M
Diluted EPS
-$0.78
Op. Cash Flow
-$52.43M
Free Cash Flow
-$52.99M
Gross Profit
$25.99M
Operating Income
-$71.05M
Cash & Equivalents
$121.17M
Debt / Equity
0.00×
Net Margin
-188.1%
Shares Outstanding
122.04M sh
Source: 10-K · filed 2026-03-04 · accession 0001398733-26-000018
show_chartPrice Chart
Loading chart...
feed AQST - Filings & News (Page 2)
AQST
Mar 04, 2026, 4:10 PM EST
Price at Filing:
$4.16
Real-time Price:
$3.52
Change:
-$0.640 (-15%)
Market Cap:
$434.879M
AQST
Feb 26, 2026, 8:07 AM EST
Price at Filing:
$4.14
Real-time Price:
$3.52
Change:
-$0.621 (-15%)
Market Cap:
$434.879M
AQST
Feb 02, 2026, 7:03 AM EST
Price at Filing:
$2.94
Real-time Price:
$3.52
Change:
+$0.580 (+20%)
Market Cap:
$434.879M
AQST
Jan 09, 2026, 7:18 AM EST
Price at Filing:
$3.46
Real-time Price:
$3.52
Change:
+$0.060 (+2%)
Market Cap:
$434.879M